Abstract 93P
Background
Tumor-agnostic therapies offer a novel approach in oncology by targeting molecular alterations regardless of tumor origin. The objective of this study was to assess the impact of an online continuing medical education (CME) activity on clinicians’ knowledge of these therapies and their confidence in incorporating them into personalized care.
Methods
This CME activity consisted of a 30-minute video panel discussion between 3 expert faculty with synchronised slides. Educational effect was assessed using a repeated-pair design with pre-/post-assessment. 3 multiple choice questions assessed knowledge, and 1 question rated on a Likert-type scale assessed confidence, with each individual serving as their own control. A McNemar’s test assessed significance of improvement in the percentage of correct responses to knowledge questions from pre- to post-assessment. P values < .05 are statistically significant. The activity launched on June 21, 2024, with data collected through September 18, 2024 being reported in the current study.
Results
52 oncologists and 32 pathologists who answered all the assessment questions were included in this analysis. Analysis of pre- vs post-intervention responses demonstrated a significant improvement in overall knowledge of both physician learner groups, with an average of 26% more oncologists (38% pre- vs 48% post-CME, P<.001) and 100% more pathologists (20% post- vs 40% pre-CME, P<.001) providing correct answers to knowledge-based questions, respectively. Additionally, 46% of oncologists and 47% of pathologists reported increased confidence in their understanding of the role of tumor-agnostic therapies in cancer management, and that increase was, on average, 80% and 90% among the two physician groups, respectively.
Conclusions
This analysis demonstrates the positive educational impact of an online CME activity on the essential aspects of tumor-agnostic therapies among key physician learner groups. To maximize the impact of advancements in precision oncology, it will be important to educate clinicians on the latest developments and facilitate their application in real-world settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.